Free Trial

STERIS (STE) Competitors

STERIS logo
$245.09 +0.09 (+0.04%)
Closing price 05/30/2025 03:59 PM Eastern
Extended Trading
$247.86 +2.78 (+1.13%)
As of 05/30/2025 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STE vs. BDX, EW, IDXX, RMD, DXCM, PODD, BAX, HOLX, MASI, and GMED

Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Insulet (PODD), Baxter International (BAX), Hologic (HOLX), Masimo (MASI), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry.

STERIS vs.

Becton, Dickinson and Company (NYSE:BDX) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Becton, Dickinson and Company received 261 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 62.03% of users gave Becton, Dickinson and Company an outperform vote while only 59.38% of users gave STERIS an outperform vote.

CompanyUnderperformOutperform
Becton, Dickinson and CompanyOutperform Votes
606
62.03%
Underperform Votes
371
37.97%
STERISOutperform Votes
345
59.38%
Underperform Votes
236
40.62%

Becton, Dickinson and Company has higher revenue and earnings than STERIS. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and Company$20.87B2.37$1.71B$5.2432.93
STERIS$5.46B4.41$378.24M$6.2039.53

STERIS has a net margin of 8.66% compared to Becton, Dickinson and Company's net margin of 8.47%. Becton, Dickinson and Company's return on equity of 15.74% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
Becton, Dickinson and Company8.47% 15.74% 7.29%
STERIS 8.66%13.91%8.64%

In the previous week, Becton, Dickinson and Company had 2 more articles in the media than STERIS. MarketBeat recorded 30 mentions for Becton, Dickinson and Company and 28 mentions for STERIS. STERIS's average media sentiment score of 1.15 beat Becton, Dickinson and Company's score of 1.09 indicating that STERIS is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Becton, Dickinson and Company
23 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
STERIS
18 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive

87.0% of Becton, Dickinson and Company shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Comparatively, 1.1% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Becton, Dickinson and Company has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, STERIS has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

Becton, Dickinson and Company currently has a consensus target price of $221.44, indicating a potential upside of 28.35%. STERIS has a consensus target price of $263.83, indicating a potential upside of 7.65%. Given Becton, Dickinson and Company's higher possible upside, equities analysts plainly believe Becton, Dickinson and Company is more favorable than STERIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Becton, Dickinson and Company
0 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.36
STERIS
0 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.63

Becton, Dickinson and Company pays an annual dividend of $4.16 per share and has a dividend yield of 2.4%. STERIS pays an annual dividend of $2.28 per share and has a dividend yield of 0.9%. Becton, Dickinson and Company pays out 79.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. STERIS pays out 36.8% of its earnings in the form of a dividend. Becton, Dickinson and Company has raised its dividend for 53 consecutive years and STERIS has raised its dividend for 20 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

STERIS beats Becton, Dickinson and Company on 12 of the 21 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STE vs. The Competition

MetricSTERISSurgical appliances & supplies IndustryMedical SectorNYSE Exchange
Market Cap$24.08B$9.60B$5.41B$19.49B
Dividend Yield0.94%1.29%5.28%3.90%
P/E Ratio52.0421.0126.8534.76
Price / Sales4.4163.67405.1239.18
Price / Cash15.7319.6738.2517.51
Price / Book3.754.976.784.74
Net Income$378.24M$284.66M$3.23B$1.02B
7 Day Performance0.77%2.44%1.29%1.28%
1 Month Performance9.10%-2.16%6.84%5.03%
1 Year Performance9.97%-19.05%25.24%5.21%

STERIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STE
STERIS
4.6764 of 5 stars
$245.09
+0.0%
$263.83
+7.6%
+9.8%$24.08B$5.46B52.0416,000Positive News
Analyst Forecast
Insider Trade
Short Interest ↓
BDX
Becton, Dickinson and Company
4.9818 of 5 stars
$171.49
-0.5%
$221.44
+29.1%
-23.9%$49.15B$20.87B28.4977,000Positive News
EW
Edwards Lifesciences
4.6067 of 5 stars
$74.98
+0.3%
$80.20
+7.0%
-11.2%$43.98B$5.52B10.7617,300Positive News
IDXX
IDEXX Laboratories
3.4196 of 5 stars
$501.57
-0.6%
$536.00
+6.9%
+2.6%$40.34B$3.93B47.0110,800Positive News
Analyst Downgrade
RMD
ResMed
4.18 of 5 stars
$243.03
-1.0%
$259.33
+6.7%
+16.8%$35.63B$5.02B28.698,160Positive News
DXCM
DexCom
4.7868 of 5 stars
$84.51
-0.4%
$98.00
+16.0%
-27.4%$33.14B$4.15B59.107,600Positive News
Analyst Forecast
Insider Trade
PODD
Insulet
4.2024 of 5 stars
$321.36
+0.1%
$308.00
-4.2%
+84.4%$22.62B$2.20B55.502,600Positive News
Analyst Forecast
BAX
Baxter International
4.5805 of 5 stars
$30.16
-0.4%
$37.25
+23.5%
-8.8%$15.48B$10.77B-23.5660,000Short Interest ↓
HOLX
Hologic
4.6593 of 5 stars
$54.28
-0.4%
$77.42
+42.6%
-14.4%$12.10B$4.03B17.126,940Analyst Forecast
Short Interest ↑
MASI
Masimo
4.2023 of 5 stars
$150.13
+0.1%
$191.60
+27.6%
+27.9%$8.14B$2.13B103.546,200Trending News
Analyst Downgrade
Short Interest ↑
Analyst Revision
GMED
Globus Medical
4.8161 of 5 stars
$59.00
+0.7%
$94.00
+59.3%
-11.1%$8.11B$2.51B78.662,600Analyst Forecast

Related Companies and Tools


This page (NYSE:STE) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners
OSZAR »